Nov 3
PG · PROCTER & GAMBLE Co
$167.10
-0.22 (-0.13%)
At close · Nov 5
Return incl. dividend (before tax)
Market Cap
$389.13B
Shares
2.32B
Volume · Nov 5
16.29M
Avg daily vol (3M)
9.27M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$167.10
Open$169.00
Day$166.32–170.52
52W close$138.04–167.32
Avg vol 30d10.0M
Short int22.1M · 1.0% of shares · 2.4d
Short vol42%
Last earningsOct 22, 2026
DataJan 2020–Nov 2026
Filing10-Q · Oct 22
Up next
Jan 21, 2027
Est · unconfirmed
· in 11 wks
Latest documents
2026
Nov 2
Current report
8-K
Other events
The Procter & Gamble Company closed an underwritten public offering of $352,231,000 aggregate principal amount of Floating Rate Notes due November 2, 2076 on November 2, 2026.
Oct 30
Current report
8-K
Other events
The Procter & Gamble Company closed an underwritten public offering of $750,000,000 of 5.125% Notes due October 30, 2031; $750,000,000 of 5.300% Notes due October 30, 2033; $1,250,000,000 of 5.450% Notes due October 30, 2036; and $1,250,000,000 of 5.900% Notes due October 30, 2056.
Oct 22
Earnings call
Q1 2027 earnings call
Procter & Gamble reported first-quarter fiscal 27 organic sales growth of 4.0%, maintained fiscal 27 guidance of one to three percent sales growth and core EPS growth of 0 to 3%, and expects a $1.9 billion after-tax earnings headwind.
Oct 22
Quarterly report
10-Q
FY2027 Q1, ended Sep 30
Quarterly report for FY2027 Q1
P&G reported net sales of $23.3 billion, up 4.0%, and diluted EPS of $1.97 and Core EPS of $2.00, both up 1%. It completed the $3.9 billion Thorne acquisition on October 1, 2026.
Revenue $23.28B
▲ 4.0%
Net income $4.73B
▼ 0.4%
Diluted EPS $1.97
▲ 1.0%
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$87.92B
Trailing 12 months
Net income (TTM)
$16.03B
Trailing 12 months
Revenue growth YoY
+4.0%
Year over year
Operating margin
22.6%
Trailing 12 months
P / E (TTM)
25.2
Trailing earnings · reciprocal yield 4.0%
FCF yield
3.9%
TTM · current market cap
Return on invested capital
19.9%
Trailing 12 months
Net cash
−$23.56B
Latest balance sheet
Dividend yield
2.6%
Trailing 12 months
Shares change YoY
-1.2%
Year over year · fewer shares
Price change (1Y)
+13.7%
Trailing year
Short interest
1.0%
Latest settlement · 2.4 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q1 FY27 earnings call · Oct 22, 2026
Q1 FY27
TL;DR. P&G delivered a strong fiscal 2027 first quarter, with organic sales up 4.0%, volume up 2.4%, and all 10 categories and six regions growing. The company maintained organic sales, core EPS, and free-cash-flow guidance, but raised the commodity-cost headwind and expects materially higher input-cost pressure in the second half.
Bullish
- + P&G maintained its full-year organic sales, core EPS, and free-cash-flow productivity guidance ranges. new
- + Productivity savings reached 250 basis points of core operating margin. new
Bearish
- − Higher input-cost pressure is expected to increase materially in the second half of fiscal 2027. new
- − Global aggregate market share was flat year over year. new
- − Organic sales guidance includes a 30-to-50-basis-point headwind from portfolio exits. new
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very Low
Market backdrop
VIX 16.6 · calm
Equity put/call 0.44
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
+10%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+18%
trailing
YTD return
+17%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $152 › 200d $149 — 50d above 200d
Institutional flow
Distributing
2,295 of 4,070 funds reported for Sep 30 · net -9.4M sh shares · +71 new
Insider flow
Distributing
Net -$31.5M over 90 days · 100% sells
Short interest
Falling
0.95% of shares out · ▼ -9.6% MoM · 2.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
4,070 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
EPS growth
+2%
Y/Y
Free cash flow
$15.1B
Valuation
P/E 25.3
below peers
Balance sheet
$24.2B
net debt
Quant / Vol
risk profile
Volatility
21%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Oct 22, 2026
Core earnings per share
· fiscal 2027
Non-GAAP
Maintained
$6.89 – $7.11
Jul 29, 2026
$6.89 – $7.11
changed to
Oct 22, 2026
$6.89 – $7.11
Combined headwind per share
· fiscal 2027
$0.79
Core effective tax rate
· fiscal 2027
Non-GAAP
Raised
20% – 21%
Jul 29, 2026
20%
changed to
Oct 22, 2026
20% – 21%
Dividends
· fiscal 2027
at least $10B
Common shares
· fiscal 2027
$5B
Previous outlook
earlier release
· from the Earnings Call filed Jul 29, 2026
Still-open targets the latest release did not restate under the same label.
Capital spending
· fiscal 27
4.5% – 5.5%
Dividends
· fiscal 27
at least $10B
Share repurchase
· fiscal 27
$5B
Total cash return to shareholders
· fiscal 27
$15B
Foreign exchange headwind
· fiscal 27
$50M
Cost headwind
· fiscal 27
$1B
Adjusted free cash flow productivity
· fiscal 27
85% – 90%
Common stock repurchases
· fiscal 27
$5B
Organic sales
· fiscal year
1% – 3%
Prior guidance
period ended
· from the 8-K filed Apr 24, 2026
Core effective tax rate
· fiscal 2026
20% – 21%
Adjusted free cash flow productivity
· fiscal 2026
85% – 90%
Guided vs delivered
· last 1 settled
Diluted net earnings per share
fiscal 2024
guided $6.25 – $6.43
$6.02
Miss −5.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $152 › 200d $149 — 50d above 200d
Institutional flow
Distributing
2,295 of 4,070 funds reported for Sep 30 · net -9.4M sh shares · +71 new
Insider flow
Distributing
Net -$31.5M over 90 days · 100% sells
Short interest
Falling
0.95% of shares out · ▼ -9.6% MoM · 2.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
4,070 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $138
Now $167 · 99%
Range high $167
vs 200-day avg +12%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted free cash flow non-GAAP | 15.8B | fiscal 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Operating Cash Flow $19.56B
-$4.41B Capital Spending
+$688M 2017 U.S. Tax Act Payments
= Adjusted Free Cash Flow $15.84B
|
|||
| Adjusted free cash flow productivity non-GAAP | 100% | fiscal 2026 filing | — |
| Consecutive years of dividend increases | 70 | fiscal 2026 filing | — |
| Consecutive years of dividend payments | 136 | fiscal 2026 filing | — |
| Core EPS non-GAAP | $6.89 | fiscal year ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Diluted net earnings per common share (1) $6.62
+$0.37 Incremental Restructuring
-$0.11 Glad Joint Venture Agreement
= Core EPS $6.89
|
|||
| Global market share of the Beauty segment | 0.3 | fiscal 2026 filing | — |
| Global market share of the Health Care segment | 0.4 | fiscal 2026 filing | — |
| Manufacturing sites in other countries | 72 | fiscal 2026 filing | — |
| Manufacturing sites in the U.S. | 24 | fiscal 2026 filing | — |
| Organic sales | 1% | fiscal 2026 filing | — |
| Organic sales growth - Beauty non-GAAP | 5% | fiscal year ended June 30, 2026 filing | — |
| Sales to Walmart Inc. and its affiliates (% of total sales) | 16% | fiscal 2026 filing | — |
| Top ten customers (% of total net sales) | 43% | fiscal 2026 filing | — |
| Volume | 4% | fiscal 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PG
this stock
PROCTER & GAMBLE Co
|
$389.13B | +16.6% | +3.3% | 25.3 | 1.0% |
|
UL
Unilever PLC
|
$145.80B | +3.5% | — | — | 0.0% |
|
CL
Colgate Palmolive Co
|
$78.51B | +24.9% | +1.7% | 38.6 | 2.2% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$48.32B | — | — | — | 0.0% |
|
EL
Estee Lauder Companies Inc
|
$40.60B | +2.8% | +5.0% | 110.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PG | +4.1% | +11.0% | +18.0% | +3.4% | +16.6% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +8.8% | +16.3% | +18.9% | +6.4% | +9.1% |
Capital returns
Latest dividend
$1.089
/ share · ex Oct 23, 2026
Paid (TTM)
$4.324
/ share · 4 payouts
Dividend yield (TTM, derived)
2.59%
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
80424
CUSIP
742718109
13F (30d)
2299 filings
2185 filers
Visit website
Investor relations